CHT101 clinical trials
Also written CHT101.
How each study uses CHT101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CHT101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CHT101
- 5
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Tianjin Medical University Cancer Institute and Hospital (3) · Nanjing Miracle Biotechnology Co., Ltd. (1) · Zhejiang University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test CHT101.
- Apr 2027A Clinical Study of CHT101 in CD70-Positive Advanced Solid TumorsPhase 1 · Tianjin Medical University Cancer Institute and Hospital
- Apr 2027A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid TumorsPhase 1 · Zhejiang University
Studies
Open first, then newest update. How each study uses CHT101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic MalignanciesNot yet recruitingPhase 1Nanjing Miracle Biotechnology Co., Ltd.NCT07809139Written as CHT101
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN）Not yet recruitingPhase 1Tianjin Medical University Cancer Institute and HospitalNCT07496073Written as CHT 101
- A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesRecruitingPhase 1Tianjin Medical University Cancer Institute and HospitalNCT06914037Written as CHT101
- A Clinical Study of CHT101 in CD70-Positive Advanced Solid TumorsRecruitingPhase 1Tianjin Medical University Cancer Institute and HospitalNCT06730659Written as CHT101
- A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid TumorsNot yet recruitingPhase 1Zhejiang UniversityNCT06383507Written as CHT101